Matching articles for "albuterol"
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 2, 2024; (Issue 1710)
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Comparison Table: Inhaled Drugs for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 2, 2024; (Issue 1710)
...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
The Medical Letter on Drugs and Therapeutics • March 18, 2024; (Issue 1698)
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed...
The FDA has approved Airsupra (AstraZeneca), a
metered-dose inhaler containing the short-acting
beta2-agonist (SABA) albuterol and the inhaled
corticosteroid (ICS) budesonide, for use as needed for
treatment or prevention of bronchoconstriction and to
reduce the risk of exacerbations in patients ≥18 years
old with asthma. Airsupra is the first combination of
a SABA and an ICS to become available in the US. It is
not approved for use as maintenance therapy.
Table: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
...
View the table: Some Inhaled Drugs for Treatment of Asthma
Table: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
...
View the table: Correct Use of Inhalers for Asthma
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 14, 2020; (Issue 1613)
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Large-Volume, Preservative-Free Albuterol Concentrate
The Medical Letter on Drugs and Therapeutics • November 2, 2020; (Issue 1610)
The short-acting beta2-agonist albuterol sulfate has
recently become available as a large-volume (20 mL),
preservative-free concentrate (albuterol inhalation
solution 0.5% – Nephron Pharmaceuticals)...
The short-acting beta2-agonist albuterol sulfate has
recently become available as a large-volume (20 mL),
preservative-free concentrate (albuterol inhalation
solution 0.5% – Nephron Pharmaceuticals) that
can be used to prepare solutions for administration
of continuous nebulized albuterol (CNA). CNA is
commonly used (off-label) for acute treatment of
severe asthma exacerbations in hospitalized patients,
particularly children. Many hospitals have been
using a 20-mL multidose bottle of 0.5% albuterol that
contains the preservative benzalkonium chloride (BAC)
for this purpose. Until now, preservative-free albuterol
was only available in 0.5-mL single-dose vials.
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Several guidelines
and review articles on COPD treatment have been
published in recent years. Treatment of acute
exacerbations is not discussed here.
Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for Treatment of COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • September 7, 2020; (Issue 1606)
...
View the Table: Correct Use of Inhalers for COPD
OTC Primatene Mist Returns
The Medical Letter on Drugs and Therapeutics • January 28, 2019; (Issue 1564)
The FDA has approved over-the-counter (OTC) sale
of inhaled epinephrine (Primatene Mist – Amphastar),
a nonselective alpha and beta agonist, for temporary
relief of mild symptoms of intermittent asthma...
The FDA has approved over-the-counter (OTC) sale
of inhaled epinephrine (Primatene Mist – Amphastar),
a nonselective alpha and beta agonist, for temporary
relief of mild symptoms of intermittent asthma in
patients ≥12 years old who have been diagnosed with
mild intermittent asthma by a healthcare professional.
The original version of Primatene Mist, which was
approved by the FDA in 1967, was removed from the
market in 2011 because the metered-dose inhaler (MDI)
contained ozone-depleting chlorofluorocarbon (CFC)
propellants; the new MDI contains hydrofluoroalkane
(HFA) propellants.
Drugs for Cough
The Medical Letter on Drugs and Therapeutics • December 17, 2018; (Issue 1562)
Acute cough (<3 weeks in duration) generally does
not require pharmacologic treatment, especially in
children. Suppression of productive cough may be
harmful. Management of patients with cough...
Acute cough (<3 weeks in duration) generally does
not require pharmacologic treatment, especially in
children. Suppression of productive cough may be
harmful. Management of patients with cough should
include elimination of any precipitating factor (e.g.,
cigarette smoking) and treatment of any underlying
cause such as upper airway cough syndrome,
gastroesophageal reflux disease, asthma, or other
pulmonary disease.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed...
The goal of asthma treatment is to control symptoms
and prevent exacerbations. Management of acute
exacerbations of asthma is not discussed here.
Comparison Table: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
...
View the Comparison Table: Some Inhaled Drugs for Treatment of Asthma
Comparison Table: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • August 28, 2017; (Issue 1528)
...
View the Comparison Table: Correct Use of Inhalers
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated guidelines
for treatment of COPD have been published in
recent years.
Comparison Table: Inhaled Short-Acting Bronchodilators for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Comparison Table: Inhaled Short-Acting Bronchodilators for COPD
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
...
View the Table: Correct Use of Inhalers for COPD
In Brief: A New Albuterol Inhaler (ProAir RespiClick) for Asthma
The Medical Letter on Drugs and Therapeutics • October 26, 2015; (Issue 1480)
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir...
The short-acting beta2-agonist albuterol sulfate is now available as a dry powder for inhalation (ProAir RespiClick – Teva) for prevention and treatment of broncho spasm in patients ≥12 years old. ProAir RespiClick is the only short-acting beta2-agonist dry powder inhaler available in the US.
![](images/TML1480c-1.png)
Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which are breath-actuated, do not require a propellant and do not have to be primed before use. They do not require coordination of inhalation with actuation, but patients must be capable of performing a rapid, deep inhalation, which might be difficult during a severe asthma attack.
The recommended dose of ProAir RespiClick for treatment of bronchospasm is 2 inhalations, but 1 inhalation may be sufficient for some patients. The dose can be repeated every 4-6 hours as needed. For prevention of exercise-induced bronchospasm, the recommended dosage is 2 inhalations 15-30 minutes before exercise.
Each ProAir RespiClick inhaler includes a dose counter. Opening the mouthpiece cap readies a dose for administration and causes the counter to count down by 1; closing the cap without inhaling the medication wastes that dose. The inhaler should be cleaned with a dry cloth as needed.
ProAir RespiClick may contain trace levels of milk proteins; it is contraindicated for use in patients with a history of a severe hypersensitivity reaction to milk proteins.
Download complete U.S. English article
![](images/TML1480c-1.png)
Metered-dose inhalers (MDIs) use a hydrofluoroalkane (HFA) propellant. They require coordination of inhalation with actuation; using them with a valved holding chamber minimizes this need, but decreases portability because of the size of the chamber. Dry powder inhalers such as ProAir RespiClick, which are breath-actuated, do not require a propellant and do not have to be primed before use. They do not require coordination of inhalation with actuation, but patients must be capable of performing a rapid, deep inhalation, which might be difficult during a severe asthma attack.
The recommended dose of ProAir RespiClick for treatment of bronchospasm is 2 inhalations, but 1 inhalation may be sufficient for some patients. The dose can be repeated every 4-6 hours as needed. For prevention of exercise-induced bronchospasm, the recommended dosage is 2 inhalations 15-30 minutes before exercise.
Each ProAir RespiClick inhaler includes a dose counter. Opening the mouthpiece cap readies a dose for administration and causes the counter to count down by 1; closing the cap without inhaling the medication wastes that dose. The inhaler should be cleaned with a dry cloth as needed.
ProAir RespiClick may contain trace levels of milk proteins; it is contraindicated for use in patients with a history of a severe hypersensitivity reaction to milk proteins.
Download complete U.S. English article
Drugs for Asthma and COPD
The Medical Letter on Drugs and Therapeutics • August 1, 2013; (Issue 132)
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young...
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young children and the elderly, use MDIs effectively.
VHCs have one-way valves that prevent the patient
from exhaling into the device, minimizing the need for
coordinated actuation and inhalation. Spacers are
tubes or chambers placed between the canister and a
face mask or mouthpiece, which also avoids the need
to coordinate actuation and inhalation. Both VHCs
and spacers retain the larger particles emitted from the
MDI, decreasing their deposition in the oropharynx
and leading to a higher proportion of small respirable
particles being inhaled.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • February 1, 2012; (Issue 114)
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers....
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers. Non-chlorinated
hydrofluoroalkane (HFA) propellants, which do
not deplete the ozone layer, are being used instead.
Drugs for Treatment of ADHD
The Medical Letter on Drugs and Therapeutics • May 1, 2011; (Issue 105)
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5%
of school-age children, most often in boys, and frequently persists into young...
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5%
of school-age children, most often in boys, and frequently persists into young adulthood.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 99)
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease...
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease such as
acute exacerbations. Other guidelines for treatment of
this condition have been published or updated in
recent years.
Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)
The Medical Letter on Drugs and Therapeutics • May 31, 2010; (Issue 1339)
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the
FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and...
Two combinations of an inhaled corticosteroid with an inhaled long-acting beta2-agonist are approved by the
FDA for use in patients with COPD: fluticasone/salmeterol (Advair Diskus) and budesonide/formoterol
(Symbicort). A Medical Letter reader has questioned the safety of using corticosteroid inhalers in patients
with this disorder. No single-agent inhaled corticosteroid inhaler is approved for this indication.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 76)
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become...
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2007; (Issue 63)
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such...
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
A Levalbuterol Metered-Dose Inhaler (Xopenex HFA) for Asthma
The Medical Letter on Drugs and Therapeutics • March 13, 2006; (Issue 1230)
Levalbuterol, the R-isomer of the beta-2 adrenergic agonist albuterol, is now available in the US as a metered-dose inhaler (Xopenex HFA - Sepracor) for treatment of asthma in patients ≥ 4 years old....
Levalbuterol, the R-isomer of the beta-2 adrenergic agonist albuterol, is now available in the US as a metered-dose inhaler (Xopenex HFA - Sepracor) for treatment of asthma in patients ≥ 4 years old. Levalbuterol has been available since 1999 in a nebulizer solution for treatment of bronchospasm in patients ≥ 6 years old.1 Outside the US, albuterol is called salbutamol, and levalbuterol is levosalbutamol.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • May 1, 2005; (Issue 33)
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other...
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740).
Prilosec, Nexium and Stereoisomers
The Medical Letter on Drugs and Therapeutics • June 23, 2003; (Issue 1159)
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram...
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • October 1, 2002; (Issue 2)
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment...
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov).
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • January 7, 2002; (Issue 1121)
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Formoterol (Foradil Aerolizer) For Asthma
The Medical Letter on Drugs and Therapeutics • May 14, 2001; (Issue 1104)
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
A Combination of Fluticasone and Salmeterol For Asthma
The Medical Letter on Drugs and Therapeutics • April 16, 2001; (Issue 1102)
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with...
Fluticasone propionate, an inhaled corticosteroid, and salmeterol xinafoate, a long-acting beta2-adrenergic agonist, are now available together in a dry-powder inhaler for maintenance treatment of patients with asthma. The new combination is not recommended for treatment of acute bronchospasm or for treatment of children less than 12 years old.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • March 6, 2000; (Issue 1073)
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow....
Asthma is a chronic inflammatory disorder of the airways; inflammation caused by allergens, viral respiratory infections or other stimuli leads to bronchial hyperresponsiveness and obstruction of airflow. Anti-inflammatory drugs, particularly inhaled corticosteroids, are central to its management.
Levalbuterol for Asthma
The Medical Letter on Drugs and Therapeutics • June 4, 1999; (Issue 1054)
Levalbuterol, the R-isomer of racemic albuterol, has been approved by the FDA for prevention and treatment of bronchospasm in patients at least 12 years...
Levalbuterol, the R-isomer of racemic albuterol, has been approved by the FDA for prevention and treatment of bronchospasm in patients at least 12 years old.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • January 15, 1999; (Issue 1044)
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of...
Asthma is a chronic inflammatory disorder, with inflammation caused by allergens or other stimuli leading to bronchial hyperresponsiveness and obstruction of airflow.
Salmeterol
The Medical Letter on Drugs and Therapeutics • April 29, 1994; (Issue 921)
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of...
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.